News | October 09, 2025
Briefs: Panacea Biotec and Shukra Pharmaceuticals
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Panacea Biotec receives acceptance from CMSS for supply of bOPV
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
